Isogenica Limited Enters into a License Agreement with Centocor Research And Development, Inc.
Published: Sep 12, 2008
Under the terms of the agreement, Isogenica will receive multi-million pound initial license fees paid over the first three years of the agreement as well as ongoing license maintenance fees and milestone payments associated with the clinical development of products discovered using Isogenica’s technology.
Isogenica's CIS display technology provides a novel and effective means of rapidly identifying peptides, polypeptides and antibodies that bind with high affinity and specificity to any given molecular target. The technology can also be used for enhancing the in vivo performance of peptide therapeutic and diagnostic products.
"We look forward to building a strong and fruitful relationship with Centocor and in assisting them with their therapeutic discovery activities" said Dr. Kevin FitzGerald, Isogenica's CEO. "We believe that CIS display technology provides a powerful new approach for the discovery of compounds for therapeutic and other in vivo applications."